Nyxoah S.A. (NYXH), a medical technology company, will release financial results for the fourth quarter and financial year 2023 on March 5, 2024, after market close.
The company's flagship product is Genio system, a CE-Mark validated, patient-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea. The Genio system has been available in Europe for treating Obstructive Sleep Apnea since 2019. It was granted CE mark approval in Europe for expanded use in treating patients with a Complete Concentric Collapse in October 2021.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.